查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613255

巨細胞病毒檢測市場：依測試類型、樣本類型、使用者群體、最終用途 – 2025-2030 年全球預測

Cytomegalovirus Tests Market by Test Type (Antigenemia Tests, Culture Tests, Molecular Tests), Sample Type (Blood Samples, Urine Samples), User Group, End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

巨細胞病毒檢測市場2023年估值為6.4128億美元，預計到2024年將達到6.8078億美元，複合年成長率為6.93%，預計到2030年將達到10.2506億美元。

巨細胞病毒(CMV) 檢測在 CMV 感染的診斷中起著至關重要的作用，特別是在免疫力缺乏的個體、新生兒和孕婦中。 CMV檢測包括血清學檢測、核酸增幅檢查（NAAT）和抗原血症檢測，每種檢測都有不同的敏感性和特異性。 CMV 檢測的必要性因其在預防先天性 CMV感染疾病以及移植患者和 HIV 陽性患者的管理中的重要用途而凸顯，其中早期檢測對於有效治療和最大限度地減少併發症至關重要。最終用途包括醫院、診斷中心和實驗室。

主要市場統計
基準年[2023] 64128萬美元
預測年份 [2024] 68078萬美元
預測年份 [2030] 1,025,060,000 美元
複合年成長率（%） 6.93%

推動市場成長的主要因素是人們對 CMV 相關健康問題的認知不斷提高、診斷技術的進步以及需要 CMV篩檢的器官移植數量的增加。在意識和資源不斷增加的發展中地區，存在著擴大 CMV 檢測的巨大機會。此外，人工智慧和機器學習在診斷過程中的整合提供了提高準確性和效率的途徑。然而，他們面臨著挑戰​​，包括先進檢測的高成本、新興國家缺乏認知以及血清學檢測交叉反應導致的潛在不準確性。

為了充分利用市場機會，相關人員應專注於即時檢測和行動裝置的創新，以實現在傳統實驗室環境之外進行快速且易於存取的診斷。此外，對公共衛生宣傳活動的投資可以提高意識並推動開拓市場的需求和擴張。提高檢測靈敏度和特異性的研究和開發，特別是區分性行為感染感染和潛伏性性行為感染，是潛在成長的重要領域。儘管這是一個充滿希望的市場，但仍有監管障礙和來自現有企業的競爭等挑戰，需要策略定位和合作夥伴關係。 CMV 測試市場是動態的，需要技術進步和適應不斷變化的醫療保健需求，以保持成長和創新。

市場動態：揭示快速發展的巨細胞病毒檢測市場的關鍵市場洞察

供需的動態交互作用正在改變巨細胞病毒檢測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球 CMV感染疾病盛行率不斷上升
    • 提高社會和臨床對 CMV 影響的認知
    • 全球肝臟移植數量增加
  • 市場限制因素
    • 高成本且先進測試設施的使用機會有限
  • 市場機會
    • 分子診斷創新和更快、更準確測試方法的開發
    • 利用次世代定序儀和基於 CRISPR 的技術進行 CMV 檢測
  • 市場挑戰
    • 複雜的監管環境和特定國家的報銷政策

波特的五力巨細胞病毒檢測市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解巨細胞病毒檢測市場的外部影響

外部宏觀環境因素在塑造巨細胞病毒檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析巨細胞病毒

對巨細胞病毒測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位巨細胞病毒檢測市場供應商績效評估

FPNV定位矩陣是評估巨細胞病毒檢測市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製巨細胞病毒檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，巨細胞病毒檢測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地 CMV 感染盛行率上升
      • 提高公眾和臨床對 CMV 影響的認知
      • 全球肝臟移植數量不斷增加
    • 抑制因素
      • 成本高且先進測試設施的使用機會有限
    • 機會
      • 分子診斷創新和更快、更準確測試方法的開發
      • 使用次世代定序和基於 CRISPR 的技術進行 CMV 檢測
    • 任務
      • 複雜的法規環境和特定國家的報銷政策
  • 市場區隔分析
    • 測試類型：在提高分子測試（尤其是聚合酵素鏈鎖反應）的靈敏度和特異性方面不斷取得進展
    • 最終用途：研究機構更多地使用巨細胞病毒檢測來開發疫苗
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按測試類型分類的巨細胞病毒測試市場

  • 抗原血症測試
  • 文化測試
  • 分子檢測
  • 血清學檢測

第7章依樣本類型分類的巨細胞病毒檢測市場

  • 血液樣本
  • 尿液樣本

第8章按使用者群組分類的巨細胞病毒檢測市場

  • 免疫力缺乏者
  • 新生
  • 孕婦

第9章巨細胞病毒檢測市場：依最終用途分類

  • 診斷實驗室
  • 醫院/診所
  • 調查機構

第10章美洲巨細胞病毒檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太鉅巨細胞病毒檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲巨細胞病毒檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准擴大使用默克公司的 PREVYMIS 來預防高風險腎移植患者的 CMV
    • Diasolin 在先天性 CMV 檢測方面取得突破
  • 戰略分析和建議

公司名單

  • Abbexa Ltd.
  • Abbott Laboratories
  • Accubiotech Co., Ltd
  • AdvaCare Pharma USA
  • Agilent Technologies, Inc.
  • Atlas Medical GmbH
  • Bio-Rad Laboratories, Inc.
  • Biogenix Inc. Pvt. Ltd.
  • CLONIT srl
  • Creative Diagnostics
  • CTK Biotech Inc. by SSI Diagnostica A/S
  • Diasorin SpA
  • Elabscience Bionovation Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hangzhou Realy Tech Co., Ltd.
  • Intec Products, Inc.
  • IQ Products BV
  • Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Thermo Fisher Scientific Inc
Product Code: MRR-6B0EA07975A5

The Cytomegalovirus Tests Market was valued at USD 641.28 million in 2023, expected to reach USD 680.78 million in 2024, and is projected to grow at a CAGR of 6.93%, to USD 1,025.06 million by 2030.

Cytomegalovirus (CMV) tests play a pivotal role in diagnosing CMV infections, particularly in immunocompromised individuals, newborns, and pregnant women. The scope of CMV testing encompasses serological assays, nucleic acid amplification tests (NAATs), and antigenemia assays, each offering varying levels of sensitivity and specificity. The necessity of CMV tests is underscored by their critical application in preventing congenital CMV infections and managing transplant recipients and HIV-positive patients, where early detection is crucial for effective treatment and minimizing complications. The end-use scope extends across hospitals, diagnostic centers, and research laboratories.

KEY MARKET STATISTICS
Base Year [2023] USD 641.28 million
Estimated Year [2024] USD 680.78 million
Forecast Year [2030] USD 1,025.06 million
CAGR (%) 6.93%

Market growth is primarily driven by increased awareness of CMV-related health issues, advancements in diagnostic technologies, and a rise in organ transplantation requiring CMV screening. Notable opportunities exist in expanding CMV testing in developing regions, where awareness and resources are growing. Furthermore, the integration of artificial intelligence and machine learning in diagnostic processes presents a pathway for enhanced accuracy and efficiency. However, the market faces challenges including high costs of advanced testing methods, insufficient awareness in emerging economies, and potential inaccuracies due to cross-reactivity in serological assays.

To capitalize on market opportunities, stakeholders should focus on innovation in point-of-care testing and portable devices, which allow for quicker, accessible diagnostics outside traditional laboratory settings. Additionally, investment in public health campaigns could elevate awareness, driving demand and expansion in untapped markets. R&D in improving the sensitivity and specificity of tests, particularly in distinguishing active from latent infections, marks a significant area of potential growth. Despite the lucrative potential, challenges such as regulatory hurdles and competition from established players necessitate strategic positioning and partnerships. The CMV tests market is dynamic, requiring adaptability to technological advancements and evolving healthcare needs to sustain growth and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cytomegalovirus Tests Market

The Cytomegalovirus Tests Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of CMV infections across the globe
    • Growing public and clinical awareness regarding the implications of CMV
    • Increasing number of liver transplant globally
  • Market Restraints
    • High cost and limited access to sophisticated testing facilities
  • Market Opportunities
    • Innovations in molecular diagnostics and the development of faster, more accurate testing methods
    • Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
  • Market Challenges
    • Complex regulatory landscapes and varying reimbursement policies across countries

Porter's Five Forces: A Strategic Tool for Navigating the Cytomegalovirus Tests Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cytomegalovirus Tests Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cytomegalovirus Tests Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cytomegalovirus Tests Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cytomegalovirus Tests Market

A detailed market share analysis in the Cytomegalovirus Tests Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cytomegalovirus Tests Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cytomegalovirus Tests Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cytomegalovirus Tests Market

A strategic analysis of the Cytomegalovirus Tests Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Tests Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Abbott Laboratories, Accubiotech Co., Ltd, AdvaCare Pharma USA, Agilent Technologies, Inc., Atlas Medical GmbH, Bio-Rad Laboratories, Inc., Biogenix Inc. Pvt. Ltd., CLONIT srl, Creative Diagnostics, CTK Biotech Inc. by SSI Diagnostica A/S, Diasorin S.p.A., Elabscience Bionovation Inc., F. Hoffmann-La Roche Ltd., Hangzhou Realy Tech Co., Ltd., Intec Products, Inc., IQ Products B.V., Jiangsu Macro & Micro-Test Med-Tech Co., Ltd., Meridian Bioscience, Inc. by SD Biosensor, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Antigenemia Tests, Culture Tests, Molecular Tests, and Serological Tests.
  • Based on Sample Type, market is studied across Blood Samples and Urine Samples.
  • Based on User Group, market is studied across Immunocompromised Individuals, Newborns, and Pregnant Women.
  • Based on End Use, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of CMV infections across the globe
      • 5.1.1.2. Growing public and clinical awareness regarding the implications of CMV
      • 5.1.1.3. Increasing number of liver transplant globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited access to sophisticated testing facilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in molecular diagnostics and the development of faster, more accurate testing methods
      • 5.1.3.2. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes and varying reimbursement policies across countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
    • 5.2.2. End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cytomegalovirus Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Antigenemia Tests
  • 6.3. Culture Tests
  • 6.4. Molecular Tests
  • 6.5. Serological Tests

7. Cytomegalovirus Tests Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood Samples
  • 7.3. Urine Samples

8. Cytomegalovirus Tests Market, by User Group

  • 8.1. Introduction
  • 8.2. Immunocompromised Individuals
  • 8.3. Newborns
  • 8.4. Pregnant Women

9. Cytomegalovirus Tests Market, by End Use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutions

10. Americas Cytomegalovirus Tests Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Tests Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Tests Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients
    • 13.3.2. DiaSorin's Breakthrough in Congenital CMV Detection
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbexa Ltd.
  • 2. Abbott Laboratories
  • 3. Accubiotech Co., Ltd
  • 4. AdvaCare Pharma USA
  • 5. Agilent Technologies, Inc.
  • 6. Atlas Medical GmbH
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Biogenix Inc. Pvt. Ltd.
  • 9. CLONIT srl
  • 10. Creative Diagnostics
  • 11. CTK Biotech Inc. by SSI Diagnostica A/S
  • 12. Diasorin S.p.A.
  • 13. Elabscience Bionovation Inc.
  • 14. F. Hoffmann-La Roche Ltd.
  • 15. Hangzhou Realy Tech Co., Ltd.
  • 16. Intec Products, Inc.
  • 17. IQ Products B.V.
  • 18. Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • 19. Meridian Bioscience, Inc. by SD Biosensor
  • 20. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYTOMEGALOVIRUS TESTS MARKET DYNAMICS
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY IMMUNOCOMPROMISED INDIVIDUALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY USER GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 191. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2023